B+
Bull case
20%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
TVGN
TevogenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A completed Phase 1 proof-of-concept, potential follow-on clinical development, and a possible end-2026 revenue transition could support a sharp re-rating if execution becomes visible.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Clinical, manufacturing, regulatory, and commercialization milestones remain uncertain.
Momentum
86
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $7.00 · Bear $1.70Analysis 2026-07-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $2.00
Why
Momentum86 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Clinical, manufacturing, regulatory, and commercialization milestones remain uncertain.
- • Limited cash and expected need for additional capital, with meaningful dilution risk [#SEC-10Q-2026-05-15].
- • The latest filing shows no product revenue, continuing losses, limited cash, negative stockholders' deficit, and dependence on additional financing, making dilution and execution the dominant risks [#SEC-10Q-2026-05-15].
Catalyst clock
2026-10-14
Financing and dilution remain the key near-term risk
Lead driver: Value · See fundamentals
Momentum
86
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 86.1 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-16. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$42.85M
Beta
-0.78
Shares Out
6.51M
P/E (TTM) · Derived
-0.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.15
Rev YoY
-
EPS YoY
-0.4%
Gross Margin
-
Op Margin
-
Net Debt
$6.95M
Current Ratio
0.33
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data